Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 11
2009 6
2010 24
2011 24
2012 22
2013 32
2014 30
2015 43
2016 44
2017 39
2018 31
2019 36
2020 41
2021 35
2022 32
2023 23
2024 37
2025 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

463 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Ofatumumab.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2020 Dec 4;77(24):2025-2028. doi: 10.1093/ajhp/zxaa322. Am J Health Syst Pharm. 2020. PMID: 33091123 No abstract available.
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Gärtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Häring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, Kappos L. Gärtner J, et al. Mult Scler. 2022 Sep;28(10):1562-1575. doi: 10.1177/13524585221078825. Epub 2022 Mar 10. Mult Scler. 2022. PMID: 35266417 Free PMC article. Clinical Trial.
Ofatumumab.
Zhang B. Zhang B. MAbs. 2009 Jul-Aug;1(4):326-31. doi: 10.4161/mabs.1.4.8895. Epub 2009 Jul 1. MAbs. 2009. PMID: 20068404 Free PMC article. Review.
Ofatumumab.
Sanford M, McCormack PL. Sanford M, et al. Drugs. 2010 May 28;70(8):1013-9. doi: 10.2165/11203850-000000000-00000. Drugs. 2010. PMID: 20481657 Review.
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
de Sèze J, Maillart E, Gueguen A, Laplaud DA, Michel L, Thouvenot E, Zephir H, Zimmer L, Biotti D, Liblau R. de Sèze J, et al. Front Immunol. 2023 Mar 23;14:1004795. doi: 10.3389/fimmu.2023.1004795. eCollection 2023. Front Immunol. 2023. PMID: 37033984 Free PMC article. Review.
463 results